Clinical Trial: RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults with Focal Onset Seizures

U.S., Jan. 30 -- ClinicalTrials.gov registry received information related to the study (NCT06798896) titled 'RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults with Focal Onset Seizures' on Jan. 16.

Brief Summary: This is a Phase 2 double-blind, randomized, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy, safety, and tolerability of SPN-817 in adults with focal onset seizures.

Study Start Date: Dec. 30, 2024

Study Type: INTERVENTIONAL

Condition: Focal Onset Seizures

Intervention: DRUG: SPN-817

SPN-817 starting at 0.25 mg bid up to 4.00 mg bid

DRUG: Placebo

Placebo, bid

Recruitment Status: RECRUITING

Sponsor: Supernus Pharmaceuticals, Inc.

Disclaimer: Curated by HT Syn...